^
    2d
    Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (clinicaltrials.gov)
    P2, N=34, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Trial completion
    |
    sunitinib • Recentin (cediranib) • Leukine (sargramostim) • Neupogen (filgrastim) • loperamide
    21d
    A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma (clinicaltrials.gov)
    P2/3, N=600, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF wild-type
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar) • Leukine (sargramostim)
    2ms
    Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas (clinicaltrials.gov)
    P2, N=60, Suspended, Roswell Park Cancer Institute | Not yet recruiting --> Suspended
    Trial suspension
    |
    temozolomide • SurVaxM (SVN53-67/M57-KLH peptide vaccine) • Leukine (sargramostim)
    2ms
    SESAD: Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease (clinicaltrials.gov)
    P2, N=42, Recruiting, University of Colorado, Denver | Trial completion date: Oct 2027 --> Nov 2026 | Trial primary completion date: Apr 2027 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    Leukine (sargramostim)
    2ms
    A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, University of Washington | Initiation date: Dec 2025 --> Mar 2026
    Trial initiation date
    |
    ENG (Endoglin)
    |
    cisplatin • carboplatin • paclitaxel • Halaven (eribulin mesylate) • pegylated liposomal doxorubicin • daunorubicin • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • EP-101 STEMVAC • Leukine (sargramostim)
    2ms
    Tebentafusp-tebn With LDT in Metastatic UM (clinicaltrials.gov)
    P1/2, N=109, Recruiting, Thomas Jefferson University | Not yet recruiting --> Recruiting | Trial completion date: Mar 2032 --> Aug 2032 | Trial primary completion date: May 2030 --> Oct 2030
    Enrollment open • Trial completion date • Trial primary completion date
    |
    carmustine • Kimmtrak (tebentafusp-tebn) • Leukine (sargramostim)
    3ms
    NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial (clinicaltrials.gov)
    P2, N=62, Recruiting, New Approaches to Neuroblastoma Therapy Consortium | Active, not recruiting --> Recruiting
    Enrollment open
    |
    temozolomide • irinotecan • Unituxin (dinutuximab) • Leukine (sargramostim)
    3ms
    GM-CSF With Post-Transplant Cyclophosphamide (clinicaltrials.gov)
    P2, N=38, Recruiting, Northside Hospital, Inc. | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • Leukine (sargramostim)
    3ms
    ANBL19P1: Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL) (clinicaltrials.gov)
    P2, N=41, Active, not recruiting, Children's Oncology Group | Trial completion date: Sep 2025 --> Sep 2027
    Trial completion date
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    temozolomide • irinotecan • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim)
    4ms
    STEMVAC in Patients With Early Stage Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=33, Active, not recruiting, University of Washington | Recruiting --> Active, not recruiting | Trial completion date: Jun 2026 --> Jul 2028 | Trial primary completion date: Dec 2025 --> Jul 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • HER-2 expression
    |
    EP-101 STEMVAC • Leukine (sargramostim)
    4ms
    Tebentafusp-tebn With LDT in Metastatic UM (clinicaltrials.gov)
    P1/2, N=109, Not yet recruiting, Thomas Jefferson University | Trial completion date: Feb 2027 --> Mar 2032 | Trial primary completion date: Jan 2027 --> May 2030
    Trial completion date • Trial primary completion date
    |
    carmustine • Kimmtrak (tebentafusp-tebn) • Leukine (sargramostim)
    4ms
    NCI-2018-03732: Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma (clinicaltrials.gov)
    P2, N=42, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2025 --> Sep 2026
    Trial completion date
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    cisplatin • carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim) • dexrazoxane